Opinions Split On Newly Approved Myeloma Therapies At ASH
This article was originally published in Scrip
Doctors debated which new therapies they would prefer to use for the treatment of multiple myeloma and when they thought emerging treatments should become an option for their patients, during the first day of the Annual Meeting for the American Society of Hematology (ASH).
You may also be interested in...
Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.